Neurotech International Limited (ASX: NTI) - Share Price

- Current share price for NTI : $0.013

Neurotech International Limited (NTI), an ASX-listed company, is a clinical-stage biopharmaceutical development company focused on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164.

NTI General Information ⁺

ASX Code	NTI
Website	http://www.neurotechinternational.com
Industry/Sector	Health Care Equipment
Market Cap ($M)	17
NTI Share Price	$0.013
Day High	$0.013
Day Low	$0.013
Last Close	$0.013
NTI Share Price Movement	- ( No change )

Prices as at 16:40, 15 Jun 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Neurotech International Limited (NTI) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Neurotech International Limited (NTI) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Neurotech International Limited (NTI) price-sensitive announcements

NTI - Quarterly Activities/Appendix 4C Cash Flow Report

Neurotech International Limited reported its quarterly activities and Appendix 4C cash flo

Neurotech International Limited (NTI)
29 Apr 2026 | 9:42 AM

NTI - NTI initiates First Clinical Site for Phase 3 ASD Trial

Neurotech International Limited has announced the initiation of the first clinical site fo

Neurotech International Limited (NTI)
17 Mar 2026 | 9:32 AM

NTI - Appendix 4D & Half Year Report

Neurotech International Limited reported a net loss of $696,501 for the half-year ended 31

Neurotech International Limited (NTI)
26 Feb 2026 | 6:15 PM

NTI - Positive 90-day GLP toxicology study results in non-rodents

Neurotech International Limited announced positive results from a 90-day GLP toxicology st

Neurotech International Limited (NTI)
23 Feb 2026 | 9:45 AM

Neurotech International Limited (NTI) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Neurotech International Limited (NTI) ORDINARY FULLY PAID	Health Care	$17	Quarterly Activities/Appendix 4C Cash Flow Report	29 Apr 2026 9:42AM	$0.012	$0.013	risen by 8.33%
Neurotech International Limited (NTI) ORDINARY FULLY PAID	Health Care	$17	Change of Director's Interest Notice	28 Apr 2026 3:20PM	$0.013	$0.013	fallen by 0%
Neurotech International Limited (NTI) ORDINARY FULLY PAID	Health Care	$17	Notification of cessation of securities - NTI	28 Apr 2026 3:18PM	$0.013	$0.013	fallen by 0%
Neurotech International Limited (NTI) ORDINARY FULLY PAID	Health Care	$17	Ceasing to be a substantial holder	23 Apr 2026 6:40PM	$0.012	$0.013	risen by 8.33%
Neurotech International Limited (NTI) ORDINARY FULLY PAID	Health Care	$17	Neurotech to present at Ignite Investment Summit Hong Kong	13 Apr 2026 9:19AM	$0.014	$0.013	fallen by 7.14%
Neurotech International Limited (NTI) ORDINARY FULLY PAID	Health Care	$17	Change of Director's Interest Notice x 4	31 Mar 2026 6:17PM	$0.013	$0.013	fallen by 0%

NTI Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2025A	-$10.60	-$1.00	82.10%	0.00%	0.0%
2024A	-$5.07	-$0.60	-42.90%	0.00%	0.0%
2023A	-$7.79	-$1.00	104.20%	0.00%	0.0%

NTI Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
Cochlear Limited (COH)	$6,785M	0.0171	-0.1883	0.0862	17.3370	21.3587	19.6645	4.14%	3.34%	3.57%
Fisher & Paykel Healthcare Corporation Limited (FPH)	$18,928M	0.1388	0.1349	0.1884	48.7373	42.9447	36.1363	1.35%	1.44%	1.63%
Neurotech International Limited (NTI)	$17M	0.8214	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
ResMed Inc. (RMD)	$15,833M	0.3087	9.7634	0.0805	190.6465	17.7125	16.3927	1.21%	1.27%	1.34%

NTI Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	4.64	0.00
Market	0.29	13.20	1.18	0.70
Sector	0.58	21.30	1.59	3.26

NTI Directors

Name	Position	Start Date
Mr Anthony Filippis	Chief Executive Officer, Managing Director	1 Feb 2025
Mr Robert (Max) Maxwell Johnston	Non-Executive Director	19 Apr 2024
Mr Gerald Quigley	Non-Executive Director, Director of Public Relations	7 Jul 2022
Mr Mark Davies	Non-Executive Director, Non-Executive Chairman	16 Apr 2019

Neurotech International Limited (NTI) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
30 Mar 2026	JOHNSTON, Robert (Max)	Issued	Indirect Shares	3,571,428	$0.014	$49,999.990
30 Mar 2026	DAVIES, Mark	Issued	Indirect Shares	7,142,858	$0.014	$100,000.010
30 Mar 2026	QUIGLEY, Gerald	Issued	Indirect Shares	3,571,428	$0.014	$49,999.990

See all changes in directors' interest & trades for Neurotech International Limited (NTI) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

NTI Management

Name	Position
Alessandra Gauvin	Company Secretary

NTI Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurotech International Limited (NTI). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
94,341,233 (9.11%)	Dutch Ink Pty Ltd
60,697,522 (5.78%)	Maybank Securities Pte. Ltd
54,987,203 (5.40%)	Biotech Capital Management Pty Ltd
53,099,919 (5.10%)	Merchant Funds Management Pty Ltd

NTI Calendar of Events

Date	Event
25 February 2027	Report (Interim)
15 October 2026	Report (Annual)
28 August 2026	Report (Annual)
28 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us